NASD · Healthcare · Biotechnology · USA
Kyverna Therapeutics Inc is a micro cap company (market value under $300 million) in the Biotechnology industry.
Kyverna Therapeutics develops cell therapies for autoimmune diseases. Its lead program, mivocabtagene autoleucel, is an autologous CAR T-cell therapy that depletes CD19-expressing B cells. The company currently evaluates this therapy in clinical trials for stiff person syndrome and generalized myasthenia gravis.
From its FY2025 annual report (Form 10-K)
Intrinsic value, DCF valuation, financial health and value investing analysis for the Kyverna Therapeutics Inc stock.
Not valued: We cannot value this company yet.
17 more funds hold it; the full list is part of the paid plan.
129 more in this industry show a wider margin of safety.
We do not publish a verdict on KYTX yet. We are missing a figure this valuation depends on. We would rather say so than show a number built on a guess.
We do not publish one (as of the 2026-11-17 close). We are missing a figure this valuation depends on. We would rather say so than show a number built on a guess.